Compare Incyte Corporation (INCY) vs Sea Limited (SE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Sea Limited — how do they compare? Incyte Corporation trades at $117 (market cap $23.11B), while Sea Limited trades at $106.21 (market cap $64.73B). The key difference: Sea Limited is far larger — about 2.8× Incyte Corporation's market cap, and Incyte Corporation is trading nearer its 52-week high, Sea Limited nearer its low. Which is the better fit depends on your goals.
| INCY | SE | |
|---|---|---|
Market Cap | $23.11B | $64.73B |
Sector | Health | Media |
52-Week High | $118.52 | $196.50 |
52-Week Low | $67.38 | $78.16 |
Enterprise Value | $19.13B | $57.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $117.39, up 0.12% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $112.78. The company reported strong Q1 2026 earnings of $1.81 per share, beating expectations, and maintains robust profitability with a net income margin of 26.71%. Recent developments include a collaboration with Halozyme for cancer therapy and positive regulatory updates for Opzelura in Europe.
Outlook remains positive driven by earnings growth and pipeline advancements, though risks include competitive pressures and reliance on key products. The stock offers potential upside to the high target of $140, supported by institutional interest and solid cash flow generation, but investors should monitor execution on upcoming Q2 results.
Sea Limited (SE) trades at $106.26, up 2.12% with a neutral technical signal. The company shows strong revenue growth, reaching $22.94 billion in 2025 with a net income margin of 6.36%. Recent earnings beat expectations in Q1 2026 but missed in prior quarters. Analyst sentiment remains bullish with a $131 consensus price target, though insider selling has drawn attention amid a 30% stock decline over the past year.
The outlook is mixed: robust fundamentals and analyst support suggest upside potential, but risks include earnings volatility, competitive pressures, and geopolitical factors affecting sentiment. The stock's valuation at a P/E of 41.61 requires sustained growth to justify current levels, making execution critical for future performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Sea Limited
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →
